Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certai...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Mengling, Huang, Qianrui, Xie, Yao, Wu, Xuyi, Ma, Hongbo, Zhang, Yiwen, Xia, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917703/
https://www.ncbi.nlm.nih.gov/pubmed/35279217
http://dx.doi.org/10.1186/s13045-022-01242-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917703/
https://www.ncbi.nlm.nih.gov/pubmed/35279217
http://dx.doi.org/10.1186/s13045-022-01242-2

Ejemplares similares